Biocept

Biocept Shares Outstanding

Delisted

The The number of shares of Biocept (BIOC) as of Nov 4, 2026 is 17.78 M. In the previous year, The number of shares was 17.78 M — a change of 0.00% (lower).

Shares Outstanding

17.78 M

YoY

0.00%

Last updated:

In 2022, Biocept had 17.78 M outstanding stocks, a 0.00% change from the 17.78 M stocks in the previous year.

The Biocept Shares Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shares Outstanding
Date
Shares Outstanding
Jan 1, 2019
17.78 M USD
Jan 1, 2020
17.78 M USD
Jan 1, 2021
17.78 M USD
Jan 1, 2022
17.78 M USD
Jan 1, 2023 (e)
17.07 USD
Jan 1, 2024 (e)
17.07 USD
Jan 1, 2025 (e)
17.07 USD
Jan 1, 2026 (e)
17.07 USD
The Biocept Shares Outstanding history
YEARShares OutstandingYoY
est17.070.00%
est17.070.00%
est17.070.00%
est17.07-100.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M0.00%
17.78 M+8.89 T%
0.000.00%
0.00+19.76%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Number of shares

Biocept shares outstanding

The number of shares of Biocept was 17.07 M in 2025. This indicates how many shares Biocept is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
97,400.00 Stocks
Jan 1, 2020
446,900.00 Stocks
Jan 1, 2021
16.85 M Stocks
Jan 1, 2022
17.07 M Stocks
Jan 1, 2023 (e)
17.07 M Stocks
Jan 1, 2024 (e)
17.07 M Stocks
Jan 1, 2025 (e)
17.07 M Stocks
Jan 1, 2026 (e)
17.07 M Stocks

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Shares Outstanding Details

Evaluating Biocept's Shares Outstanding

Biocept's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Biocept’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Biocept’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Biocept’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Biocept stock

The number of shares of Biocept is 17.78 M in 2022.

The number of shares of Biocept changed from 17.78 M to 17.78 M, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of shares Biocept since 2006 – with annual values, charts, and detailed analysis.

The number of shares indicates the total number of a company's shares. This includes not only the shares available on the market, but also the shares held by shareholders and the shares retained by the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Biocept

All Key Metrics — Biocept